董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Javitt | 男 | Chairman, Interim Chief Executive Officer and Chief Scientist | 69 | 101.30万美元 | 155.83 | 2026-03-23 |
| Patrick J. Flynn | 男 | Independent Director | 77 | 9.00万美元 | 16.60 | 2026-03-23 |
| Dennis McBride | 男 | Independent Director | 72 | 3.85万美元 | 1.83 | 2026-03-23 |
| Michael Taylor | 男 | Independent Director | 51 | 未披露 | 0.83 | 2026-03-23 |
| Chaim Hurvitz | 男 | Independent Director | 65 | 7.00万美元 | 24.65 | 2026-03-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Javitt | 男 | Chairman, Interim Chief Executive Officer and Chief Scientist | 69 | 101.30万美元 | 155.83 | 2026-03-23 |
| Michael Abrams | 男 | Chief Financial Officer and Treasurer | 55 | 47.30万美元 | 1.67 | 2026-03-23 |
| Joseph Casper | 男 | Chief Operational Officer | 75 | 未披露 | 未持股 | 2026-03-23 |
董事简历
中英对照 | 中文 | 英文- Jonathan Javitt
-
Jonathan C. Javitt，于2021年5月至2022年3月担任NRX Pharmaceuticals, Inc.首席执行官兼NRX Pharmaceuticals, Inc.董事会主席，自2022年3月起，担任首席科学家并担任NRX Pharmaceuticals, Inc.董事会成员。自2015年创立以来，他一直担任公司前身NeuroRx，Inc.的董事会主席和首席执行官。在创办NeuroRX，Inc.之前，他参与了Allergan、爱尔康、EYETech、默沙东、诺华、辉瑞、Pharmacia的领先药物和医疗器械开发及商业化项目。他曾在七家成功的医疗保健 IT和生物制药初创公司中担任领导职务。他被任命为罗纳德里根总统、乔治 H.W.布什总统、克林顿总统和乔治 W 布什总统手下的医疗保健领导职务。在里根和布什的41届政府期间，他被指定为卫生与公众服务部的专家顾问。克林顿总统指定他为总统白宫行政办公室的特别政府雇员，在1993年医疗改革特别工作组任职。在布什总统的领导下，他受命领导总统信息技术咨询委员会的医疗保健委员会，并担任国防部次长的特别雇员。Javitt博士在健康结果和药物经济学领域发表了200多篇科学著作，被引用超过31,000次。Javitt博士拥有普林斯顿大学的荣誉A.B.学位、康奈尔大学的医学博士学位和哈佛大学陈公共卫生学院的公共卫生硕士学位。2015年，他被指定为优异校友，这是哈佛大学授予公共卫生学院毕业生的最高荣誉。他继续担任约翰霍普金斯医学院眼科兼职教授和波托马克政策研究所高级研究员。
Jonathan Javitt additionally served as the Company's Chief Executive Officer ("CEO") from May 2021 until March 2022 and was elected Chairman in December 2023. He was the Co founder, Chairman, and CEO of NeuroRx, Inc., which merged with the Company in May 2021. He participated in leading drug and medical device development and commercialization projects for Allergan, Alcon, Eyetech, Merck, Novartis, Pfizer, and Pharmacia and has led the Company's regulatory and clinical development efforts from their inception. He has played leadership roles in seven successful healthcare IT and biopharma start up companies. He was appointed to healthcare leadership roles under President Ronald Reagan, George H.W. Bh, Clinton and George W. Bh. During the Reagan and Bh '41 administrations, he was designated as an Expert Consultant to the Department of Health and Human Services. President Clinton designated him as a Special Government Employee of the White Hoe Executive Office of the President to serve on the 1993 Health Reform Task Force. Under President George W. Bh, he was commissioned to lead the Healthcare Committee of the President's Information Technology Advisory Committee and to serve as a Special Employee of the Undersecretary of Defense. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited more than 31,000 times. Dr. Javitt holds an A.B. with Honors from Princeton University, an M.D. from Cornell University and a Masters of Public Health from the Harvard Chan School of Public Health which designated him an Alumn of Merit. He continues to serve as an adjunct Professor of Ophthalmology at the Johns Hopkins School of Medicine and as a Senior Fellow of the Potomac Institute for Policy Studies. - Jonathan C. Javitt，于2021年5月至2022年3月担任NRX Pharmaceuticals, Inc.首席执行官兼NRX Pharmaceuticals, Inc.董事会主席，自2022年3月起，担任首席科学家并担任NRX Pharmaceuticals, Inc.董事会成员。自2015年创立以来，他一直担任公司前身NeuroRx，Inc.的董事会主席和首席执行官。在创办NeuroRX，Inc.之前，他参与了Allergan、爱尔康、EYETech、默沙东、诺华、辉瑞、Pharmacia的领先药物和医疗器械开发及商业化项目。他曾在七家成功的医疗保健 IT和生物制药初创公司中担任领导职务。他被任命为罗纳德里根总统、乔治 H.W.布什总统、克林顿总统和乔治 W 布什总统手下的医疗保健领导职务。在里根和布什的41届政府期间，他被指定为卫生与公众服务部的专家顾问。克林顿总统指定他为总统白宫行政办公室的特别政府雇员，在1993年医疗改革特别工作组任职。在布什总统的领导下，他受命领导总统信息技术咨询委员会的医疗保健委员会，并担任国防部次长的特别雇员。Javitt博士在健康结果和药物经济学领域发表了200多篇科学著作，被引用超过31,000次。Javitt博士拥有普林斯顿大学的荣誉A.B.学位、康奈尔大学的医学博士学位和哈佛大学陈公共卫生学院的公共卫生硕士学位。2015年，他被指定为优异校友，这是哈佛大学授予公共卫生学院毕业生的最高荣誉。他继续担任约翰霍普金斯医学院眼科兼职教授和波托马克政策研究所高级研究员。
- Jonathan Javitt additionally served as the Company's Chief Executive Officer ("CEO") from May 2021 until March 2022 and was elected Chairman in December 2023. He was the Co founder, Chairman, and CEO of NeuroRx, Inc., which merged with the Company in May 2021. He participated in leading drug and medical device development and commercialization projects for Allergan, Alcon, Eyetech, Merck, Novartis, Pfizer, and Pharmacia and has led the Company's regulatory and clinical development efforts from their inception. He has played leadership roles in seven successful healthcare IT and biopharma start up companies. He was appointed to healthcare leadership roles under President Ronald Reagan, George H.W. Bh, Clinton and George W. Bh. During the Reagan and Bh '41 administrations, he was designated as an Expert Consultant to the Department of Health and Human Services. President Clinton designated him as a Special Government Employee of the White Hoe Executive Office of the President to serve on the 1993 Health Reform Task Force. Under President George W. Bh, he was commissioned to lead the Healthcare Committee of the President's Information Technology Advisory Committee and to serve as a Special Employee of the Undersecretary of Defense. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited more than 31,000 times. Dr. Javitt holds an A.B. with Honors from Princeton University, an M.D. from Cornell University and a Masters of Public Health from the Harvard Chan School of Public Health which designated him an Alumn of Merit. He continues to serve as an adjunct Professor of Ophthalmology at the Johns Hopkins School of Medicine and as a Senior Fellow of the Potomac Institute for Policy Studies.
- Patrick J. Flynn
-
Patrick J. Flynn，自2021年5月起担任NRX Pharmaceuticals, Inc.董事会成员。Flynn先生是一位企业家，拥有超过35年的高级管理经验。他曾为众多成功的组织提供领导，包括初创企业和成长阶段的公司，并担任过多种职务，包括执行董事长、董事会成员、首席执行官、首席运营官、首席财务官和顾问。Flynn先生自2017年起担任公司前身NeuroRx，Inc.董事会成员。自2012年以来，Flynn先生一直担任Common Sensing Inc.的董事会成员，该公司是一家数据驱动的硬件和软件解决方案公司。此外，Flynn先生目前担任Good Measures的首席运营官，负责该公司以创新方式提供医疗保健和营养服务的日常运营。在加入Good Measures之前，Flynn先生是Predilytics，Inc.的联合创始人，并担任执行董事长。在加入Predilytics之前，Flynn先生在Health Dialog担任首席运营官和首席执行官期间贡献了他的专业知识，在那里他帮助将业务从一家早期的医疗保健服务机构发展成为世界领先的医疗保健分析、医疗保健服务和决策支持提供商之一。在担任这一职务之前，Flynn是Symmetrix的联合创始人，Symmetrix是一家专门从事医疗保健和金融服务的管理咨询公司。弗林先生的职业生涯始于美国银行，在15年的时间里，他担任过多个职位，包括世界银行副总裁和风险管理副总裁。弗林先生在宾夕法尼亚大学沃顿商学院获得了金融学学士学位。
Patrick J. Flynn has served as a member of Board since May 2021, and is the Chair of Audit Committee and Compensation Committee. Mr. Flynn previoly served on the board of directors of NeuroRx, Inc., the predecessor to company. and. Mr. Flynn is an entrepreneur with more than 35 years of senior executive experience. He has provided leadership to numero successful organizations including start ups and growth stage companies and has served in a variety of roles, including Executive Chairman, board member, CEO, COO, CFO and advisor. Additionally, Mr. Flynn served as an advisor to Good Measures where he was previoly COO and responsible for the day to day operations of the company's innovative approach to healthcare and nutrition services. Prior to joining Good Measures, Mr. Flynn was the co founder of Predilytics, Inc. and served as Executive Chairman. Before joining Predilytics, Mr. Flynn contributed his expertise as COO and then as CEO to Health Dialog, where he helped build the biness from an early stage healthcare services organization and led its successful exit to BUPA, a global insurance company. Prior to this role, Flynn was a co founder of Symmetrix, a management consulting firm specializing in healthcare and financial services. Mr. Flynn began his career with Bank of America where he held several positions over the cse of 15 years, including Vice President of World Banking and Vice President of Risk Management. Mr. Flynn earned his B.S. in Finance from the Wharton School at the University of Pennsylvania. - Patrick J. Flynn，自2021年5月起担任NRX Pharmaceuticals, Inc.董事会成员。Flynn先生是一位企业家，拥有超过35年的高级管理经验。他曾为众多成功的组织提供领导，包括初创企业和成长阶段的公司，并担任过多种职务，包括执行董事长、董事会成员、首席执行官、首席运营官、首席财务官和顾问。Flynn先生自2017年起担任公司前身NeuroRx，Inc.董事会成员。自2012年以来，Flynn先生一直担任Common Sensing Inc.的董事会成员，该公司是一家数据驱动的硬件和软件解决方案公司。此外，Flynn先生目前担任Good Measures的首席运营官，负责该公司以创新方式提供医疗保健和营养服务的日常运营。在加入Good Measures之前，Flynn先生是Predilytics，Inc.的联合创始人，并担任执行董事长。在加入Predilytics之前，Flynn先生在Health Dialog担任首席运营官和首席执行官期间贡献了他的专业知识，在那里他帮助将业务从一家早期的医疗保健服务机构发展成为世界领先的医疗保健分析、医疗保健服务和决策支持提供商之一。在担任这一职务之前，Flynn是Symmetrix的联合创始人，Symmetrix是一家专门从事医疗保健和金融服务的管理咨询公司。弗林先生的职业生涯始于美国银行，在15年的时间里，他担任过多个职位，包括世界银行副总裁和风险管理副总裁。弗林先生在宾夕法尼亚大学沃顿商学院获得了金融学学士学位。
- Patrick J. Flynn has served as a member of Board since May 2021, and is the Chair of Audit Committee and Compensation Committee. Mr. Flynn previoly served on the board of directors of NeuroRx, Inc., the predecessor to company. and. Mr. Flynn is an entrepreneur with more than 35 years of senior executive experience. He has provided leadership to numero successful organizations including start ups and growth stage companies and has served in a variety of roles, including Executive Chairman, board member, CEO, COO, CFO and advisor. Additionally, Mr. Flynn served as an advisor to Good Measures where he was previoly COO and responsible for the day to day operations of the company's innovative approach to healthcare and nutrition services. Prior to joining Good Measures, Mr. Flynn was the co founder of Predilytics, Inc. and served as Executive Chairman. Before joining Predilytics, Mr. Flynn contributed his expertise as COO and then as CEO to Health Dialog, where he helped build the biness from an early stage healthcare services organization and led its successful exit to BUPA, a global insurance company. Prior to this role, Flynn was a co founder of Symmetrix, a management consulting firm specializing in healthcare and financial services. Mr. Flynn began his career with Bank of America where he held several positions over the cse of 15 years, including Vice President of World Banking and Vice President of Risk Management. Mr. Flynn earned his B.S. in Finance from the Wharton School at the University of Pennsylvania.
- Dennis McBride
-
丹尼斯·麦克布赖德的职业生涯始于海军航空和人体工程学领域的医学科学家，曾任职于美国国防高级研究计划局（DARPA）、海军航空航天医学研究实验室、海军研究实验室、海军研究办公室、海军医学研究所等八个全国知名实验室。在以高级官员（O-6）的身份退休后，他开始领导波托马克政策研究所，并继续担任名誉主席。十年任期结束后，他被招募回国防大学，领导技术和国家安全政策中心，以高级主管-4（相当于海军少将/海军中将的文职人员）的身份结束了他的政府生涯。麦克布赖德博士曾担任内阁秘书、美国国会委员会以及企业C-Suite高管的顾问。他的教育背景包括在乔治亚大学、海军航天医学研究所（飞行外科学校）、南加州大学、伦敦经济学院和哈佛商学院正式入学，获得实验心理学博士学位、四个硕士学位，并在航空医学、系统工程科学和战略颠覆方面获得额外的博士后教育。出版广泛，1999年被教师推选为正教授。McBride博士曾在多所大学的艺术与科学、工程、公共政策和医学学院任职。在过去的12年里，麦克布赖德博士一直担任乔治城大学医学院的兼职教授和乔治城监管科学项目的联合主任。
Dennis McBride currently serves as the Chair of Nominating and Corporate Governance Committee and has served as a research professor at Virginia Tech since May 2021. Dr. McBride has led numero national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi billion dollar enterprises. Dr. McBride also served as Director of the Acquisition and Innovation Research Center for the Department of Defense from February 2022 to February 2024, and as Vice President of Strategy and Innovation at Sce America from December 2015 to December 2020. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O 6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emerit. Following his ten year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive 4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, U.S. Congressional Committees, and to corporate C Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Southern California, the London School of Economics, and Harvard Biness School, earning a Ph.D. in experimental psychology, f master's degrees, and an additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely and was elected by faculty in 1999 to full professor. Dr. McBride has served at multiple universities in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as an adjunct Professor at Georgetown University School of Medicine and co Director of Georgetown's Regulatory Science Program. - 丹尼斯·麦克布赖德的职业生涯始于海军航空和人体工程学领域的医学科学家，曾任职于美国国防高级研究计划局（DARPA）、海军航空航天医学研究实验室、海军研究实验室、海军研究办公室、海军医学研究所等八个全国知名实验室。在以高级官员（O-6）的身份退休后，他开始领导波托马克政策研究所，并继续担任名誉主席。十年任期结束后，他被招募回国防大学，领导技术和国家安全政策中心，以高级主管-4（相当于海军少将/海军中将的文职人员）的身份结束了他的政府生涯。麦克布赖德博士曾担任内阁秘书、美国国会委员会以及企业C-Suite高管的顾问。他的教育背景包括在乔治亚大学、海军航天医学研究所（飞行外科学校）、南加州大学、伦敦经济学院和哈佛商学院正式入学，获得实验心理学博士学位、四个硕士学位，并在航空医学、系统工程科学和战略颠覆方面获得额外的博士后教育。出版广泛，1999年被教师推选为正教授。McBride博士曾在多所大学的艺术与科学、工程、公共政策和医学学院任职。在过去的12年里，麦克布赖德博士一直担任乔治城大学医学院的兼职教授和乔治城监管科学项目的联合主任。
- Dennis McBride currently serves as the Chair of Nominating and Corporate Governance Committee and has served as a research professor at Virginia Tech since May 2021. Dr. McBride has led numero national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi billion dollar enterprises. Dr. McBride also served as Director of the Acquisition and Innovation Research Center for the Department of Defense from February 2022 to February 2024, and as Vice President of Strategy and Innovation at Sce America from December 2015 to December 2020. Dr. McBride began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally prominent laboratories, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O 6), he assumed leadership of the Potomac Institute for Policy Studies, where he continues to serve as President Emerit. Following his ten year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career as a Senior Executive 4 (Civilian equivalent to Rear Admiral/Vice Admiral). Dr. McBride has served as an adviser to Cabinet Secretaries, U.S. Congressional Committees, and to corporate C Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (flight surgeon school), the University of Southern California, the London School of Economics, and Harvard Biness School, earning a Ph.D. in experimental psychology, f master's degrees, and an additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely and was elected by faculty in 1999 to full professor. Dr. McBride has served at multiple universities in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as an adjunct Professor at Georgetown University School of Medicine and co Director of Georgetown's Regulatory Science Program.
- Michael Taylor
-
Michael Taylor，2016年8月至2023年2月14日担任Adi Dassler国际家族办公室财富咨询公司的合伙人，2011年6月至2016年8月担任Oppenheimer & Co. Inc.的董事总经理，该公司是一家总部位于纽约的全方位服务经纪和投资银行，专注于复杂的债务结构和交易以及多司法管辖区资本形成，并于2004年7月至2011年6月担任私人投资公司Stone & Youngberg LLC的机构固定收益交易和另类投资的董事总经理。Taylor先生的职业生涯始于摩根士丹利，是一名债券交易员。Taylor先生拥有伦敦经济学院经济学和国际关系理学学士学位。
Michael Taylor was appointed to the Board in January, 2025. Mr. Taylor is a 25 year veteran in the global credit biness, focused on special situations and capital formation, and currently serves as a consultant to Hope Therapeutics, Inc., a wholly owned subsidiary of the Company. Mr. Taylor previoly served as a Partner of the Adi Dassler International Family office alth advisory firm from August 2016 to February 14, 2023, as Managing Director at Oppenheimer & Co. Inc. from June 2011 to August 2016, a New York based full service brokerage and investment bank, focing on complex debt structuring and transactions and multijurisdictional capital formation, and as Managing Director of Institutional Fixed Income Trading and Alternative Investments at Stone & Youngberg LLC, a private investment firm, from July 2004 to June 2011. Mr. Taylor began his career with Morgan Stanley as a Bond Trader. Mr. Taylor holds a Bachelor of Science degree in Economics & International Relations from the London School of Economics. - Michael Taylor，2016年8月至2023年2月14日担任Adi Dassler国际家族办公室财富咨询公司的合伙人，2011年6月至2016年8月担任Oppenheimer & Co. Inc.的董事总经理，该公司是一家总部位于纽约的全方位服务经纪和投资银行，专注于复杂的债务结构和交易以及多司法管辖区资本形成，并于2004年7月至2011年6月担任私人投资公司Stone & Youngberg LLC的机构固定收益交易和另类投资的董事总经理。Taylor先生的职业生涯始于摩根士丹利，是一名债券交易员。Taylor先生拥有伦敦经济学院经济学和国际关系理学学士学位。
- Michael Taylor was appointed to the Board in January, 2025. Mr. Taylor is a 25 year veteran in the global credit biness, focused on special situations and capital formation, and currently serves as a consultant to Hope Therapeutics, Inc., a wholly owned subsidiary of the Company. Mr. Taylor previoly served as a Partner of the Adi Dassler International Family office alth advisory firm from August 2016 to February 14, 2023, as Managing Director at Oppenheimer & Co. Inc. from June 2011 to August 2016, a New York based full service brokerage and investment bank, focing on complex debt structuring and transactions and multijurisdictional capital formation, and as Managing Director of Institutional Fixed Income Trading and Alternative Investments at Stone & Youngberg LLC, a private investment firm, from July 2004 to June 2011. Mr. Taylor began his career with Morgan Stanley as a Bond Trader. Mr. Taylor holds a Bachelor of Science degree in Economics & International Relations from the London School of Economics.
- Chaim Hurvitz
-
Chaim Hurvitz是Nrx Pharmaceuticals, Inc.董事会的成员，自2021年5月起担任该职务。他曾担任Nrx Pharmaceuticals, Inc.前身NeuroRx, Inc.的董事会成员，任期从2015年5月开始。自2011年5月起，Hurvitz先生担任CH Health的首席执行官，这是一家私人风险投资公司。在此之前，Hurvitz先生曾于2010年10月至2014年7月担任Teva Pharmaceuticals Industries Ltd.的董事会成员。此前，他曾是Teva Pharmaceuticals Industries Ltd.的高级管理层成员，从2002年至2010年担任Teva国际集团总裁，从1992年至1999年担任Teva Pharmaceuticals Europe总裁兼首席执行官，以及从1999年至2002年担任以色列制药销售副总裁。Hurvitz先生是Galmed Pharmaceuticals Ltd.的创始投资者和董事。他目前担任以色列制造商协会的管理成员，并担任其制药部门的负责人。Hurvitz先生拥有以色列特拉维夫大学的学士学位。
Chaim Hurvitz has served as a director and Chairman of Dror Ortho Design, Inc.'s Board since August 2023 and previously served as Chairman of Private Dror from January 17, 2012, until the closing of the Share Exchange in August 2023. Mr. Hurvitz has founded and has served as chief executive officer of C.H. Health, a healthcare focused venture capital firm since May 2011. His investments through CH Health have included several successful exits including the Nasdaq IPOs of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed") and UroGen Pharma Ltd. (NASDAQ: URGN) ("UroGen"). He was previously a member of Teva's senior management, serving as the President of Teva International Group from 2002 through 2010, Vice President of Israeli Pharmaceutical Sales from 1999 through 2002 and President and CEO of Teva Pharmaceuticals Europe from 1992 through 1999. Mr. Hurvitz presently serves as the chairman of Univo Pharmaceuticals Ltd., the chairman of Shirat Hachaim Ltd., a director of Celexir, a director of Genoscience Pharma S.A.S., and a director of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) and has previously served as the chairman CTG Weld Limited, as the chairman of PolyPid Ltd. (NASDAQ: PYPD), as the chairman of Galmed, as a director of UroGen, and as a director of Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Mr. Hurvitz is also a member of management of the Manufacturers Association of Israel and Head of its Pharmaceutical branch. Mr. Hurvitz received a B.A. in political science and economics from Tel Aviv University in 1985. - Chaim Hurvitz是Nrx Pharmaceuticals, Inc.董事会的成员，自2021年5月起担任该职务。他曾担任Nrx Pharmaceuticals, Inc.前身NeuroRx, Inc.的董事会成员，任期从2015年5月开始。自2011年5月起，Hurvitz先生担任CH Health的首席执行官，这是一家私人风险投资公司。在此之前，Hurvitz先生曾于2010年10月至2014年7月担任Teva Pharmaceuticals Industries Ltd.的董事会成员。此前，他曾是Teva Pharmaceuticals Industries Ltd.的高级管理层成员，从2002年至2010年担任Teva国际集团总裁，从1992年至1999年担任Teva Pharmaceuticals Europe总裁兼首席执行官，以及从1999年至2002年担任以色列制药销售副总裁。Hurvitz先生是Galmed Pharmaceuticals Ltd.的创始投资者和董事。他目前担任以色列制造商协会的管理成员，并担任其制药部门的负责人。Hurvitz先生拥有以色列特拉维夫大学的学士学位。
- Chaim Hurvitz has served as a director and Chairman of Dror Ortho Design, Inc.'s Board since August 2023 and previously served as Chairman of Private Dror from January 17, 2012, until the closing of the Share Exchange in August 2023. Mr. Hurvitz has founded and has served as chief executive officer of C.H. Health, a healthcare focused venture capital firm since May 2011. His investments through CH Health have included several successful exits including the Nasdaq IPOs of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed") and UroGen Pharma Ltd. (NASDAQ: URGN) ("UroGen"). He was previously a member of Teva's senior management, serving as the President of Teva International Group from 2002 through 2010, Vice President of Israeli Pharmaceutical Sales from 1999 through 2002 and President and CEO of Teva Pharmaceuticals Europe from 1992 through 1999. Mr. Hurvitz presently serves as the chairman of Univo Pharmaceuticals Ltd., the chairman of Shirat Hachaim Ltd., a director of Celexir, a director of Genoscience Pharma S.A.S., and a director of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) and has previously served as the chairman CTG Weld Limited, as the chairman of PolyPid Ltd. (NASDAQ: PYPD), as the chairman of Galmed, as a director of UroGen, and as a director of Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Mr. Hurvitz is also a member of management of the Manufacturers Association of Israel and Head of its Pharmaceutical branch. Mr. Hurvitz received a B.A. in political science and economics from Tel Aviv University in 1985.
高管简历
中英对照 | 中文 | 英文- Jonathan Javitt
Jonathan C. Javitt，于2021年5月至2022年3月担任NRX Pharmaceuticals, Inc.首席执行官兼NRX Pharmaceuticals, Inc.董事会主席，自2022年3月起，担任首席科学家并担任NRX Pharmaceuticals, Inc.董事会成员。自2015年创立以来，他一直担任公司前身NeuroRx，Inc.的董事会主席和首席执行官。在创办NeuroRX，Inc.之前，他参与了Allergan、爱尔康、EYETech、默沙东、诺华、辉瑞、Pharmacia的领先药物和医疗器械开发及商业化项目。他曾在七家成功的医疗保健 IT和生物制药初创公司中担任领导职务。他被任命为罗纳德里根总统、乔治 H.W.布什总统、克林顿总统和乔治 W 布什总统手下的医疗保健领导职务。在里根和布什的41届政府期间，他被指定为卫生与公众服务部的专家顾问。克林顿总统指定他为总统白宫行政办公室的特别政府雇员，在1993年医疗改革特别工作组任职。在布什总统的领导下，他受命领导总统信息技术咨询委员会的医疗保健委员会，并担任国防部次长的特别雇员。Javitt博士在健康结果和药物经济学领域发表了200多篇科学著作，被引用超过31,000次。Javitt博士拥有普林斯顿大学的荣誉A.B.学位、康奈尔大学的医学博士学位和哈佛大学陈公共卫生学院的公共卫生硕士学位。2015年，他被指定为优异校友，这是哈佛大学授予公共卫生学院毕业生的最高荣誉。他继续担任约翰霍普金斯医学院眼科兼职教授和波托马克政策研究所高级研究员。
Jonathan Javitt additionally served as the Company's Chief Executive Officer ("CEO") from May 2021 until March 2022 and was elected Chairman in December 2023. He was the Co founder, Chairman, and CEO of NeuroRx, Inc., which merged with the Company in May 2021. He participated in leading drug and medical device development and commercialization projects for Allergan, Alcon, Eyetech, Merck, Novartis, Pfizer, and Pharmacia and has led the Company's regulatory and clinical development efforts from their inception. He has played leadership roles in seven successful healthcare IT and biopharma start up companies. He was appointed to healthcare leadership roles under President Ronald Reagan, George H.W. Bh, Clinton and George W. Bh. During the Reagan and Bh '41 administrations, he was designated as an Expert Consultant to the Department of Health and Human Services. President Clinton designated him as a Special Government Employee of the White Hoe Executive Office of the President to serve on the 1993 Health Reform Task Force. Under President George W. Bh, he was commissioned to lead the Healthcare Committee of the President's Information Technology Advisory Committee and to serve as a Special Employee of the Undersecretary of Defense. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited more than 31,000 times. Dr. Javitt holds an A.B. with Honors from Princeton University, an M.D. from Cornell University and a Masters of Public Health from the Harvard Chan School of Public Health which designated him an Alumn of Merit. He continues to serve as an adjunct Professor of Ophthalmology at the Johns Hopkins School of Medicine and as a Senior Fellow of the Potomac Institute for Policy Studies.- Jonathan C. Javitt，于2021年5月至2022年3月担任NRX Pharmaceuticals, Inc.首席执行官兼NRX Pharmaceuticals, Inc.董事会主席，自2022年3月起，担任首席科学家并担任NRX Pharmaceuticals, Inc.董事会成员。自2015年创立以来，他一直担任公司前身NeuroRx，Inc.的董事会主席和首席执行官。在创办NeuroRX，Inc.之前，他参与了Allergan、爱尔康、EYETech、默沙东、诺华、辉瑞、Pharmacia的领先药物和医疗器械开发及商业化项目。他曾在七家成功的医疗保健 IT和生物制药初创公司中担任领导职务。他被任命为罗纳德里根总统、乔治 H.W.布什总统、克林顿总统和乔治 W 布什总统手下的医疗保健领导职务。在里根和布什的41届政府期间，他被指定为卫生与公众服务部的专家顾问。克林顿总统指定他为总统白宫行政办公室的特别政府雇员，在1993年医疗改革特别工作组任职。在布什总统的领导下，他受命领导总统信息技术咨询委员会的医疗保健委员会，并担任国防部次长的特别雇员。Javitt博士在健康结果和药物经济学领域发表了200多篇科学著作，被引用超过31,000次。Javitt博士拥有普林斯顿大学的荣誉A.B.学位、康奈尔大学的医学博士学位和哈佛大学陈公共卫生学院的公共卫生硕士学位。2015年，他被指定为优异校友，这是哈佛大学授予公共卫生学院毕业生的最高荣誉。他继续担任约翰霍普金斯医学院眼科兼职教授和波托马克政策研究所高级研究员。
- Jonathan Javitt additionally served as the Company's Chief Executive Officer ("CEO") from May 2021 until March 2022 and was elected Chairman in December 2023. He was the Co founder, Chairman, and CEO of NeuroRx, Inc., which merged with the Company in May 2021. He participated in leading drug and medical device development and commercialization projects for Allergan, Alcon, Eyetech, Merck, Novartis, Pfizer, and Pharmacia and has led the Company's regulatory and clinical development efforts from their inception. He has played leadership roles in seven successful healthcare IT and biopharma start up companies. He was appointed to healthcare leadership roles under President Ronald Reagan, George H.W. Bh, Clinton and George W. Bh. During the Reagan and Bh '41 administrations, he was designated as an Expert Consultant to the Department of Health and Human Services. President Clinton designated him as a Special Government Employee of the White Hoe Executive Office of the President to serve on the 1993 Health Reform Task Force. Under President George W. Bh, he was commissioned to lead the Healthcare Committee of the President's Information Technology Advisory Committee and to serve as a Special Employee of the Undersecretary of Defense. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited more than 31,000 times. Dr. Javitt holds an A.B. with Honors from Princeton University, an M.D. from Cornell University and a Masters of Public Health from the Harvard Chan School of Public Health which designated him an Alumn of Merit. He continues to serve as an adjunct Professor of Ophthalmology at the Johns Hopkins School of Medicine and as a Senior Fellow of the Potomac Institute for Policy Studies.
- Michael Abrams
Michael Abrams，于2021年5月至2025年1月期间，在上市的生物技术公司Arch Therapeutics，Inc.担任首席财务官的TERM1，在短暂过渡角色后，他于2025年2月3日辞去该公司的职务。从2019年2月到2021年4月，Abrams先生在RiseIT Solutions，Inc.担任首席财务官，帮助该业务恢复盈利。从2009年8月至2019年2月，Abrams先生担任FitLife Brands，Inc.的首席财务官，该公司是一家上市实体，专注于开发功能性营养补充剂，以支持积极、健康的生活方式。艾布拉姆斯先生在芝加哥大学布斯商学院以优异成绩获得工商管理硕士学位，并以William F. Field校友学者的身份在马萨诸塞大学阿默斯特分校以优异成绩获得工商管理硕士学位。
Michael Abrams has served as Chief Financial Officer since November 2024. Prior to his appointment as Chief Financial Officer, Mr. Abrams served as the Chief Financial Officer of Arch Therapeutics, Inc., a publicly traded biotechnology company, from May 2021 through January 2025, which he resigned from on February 3, 2025 after a brief transitional role. From February 2019 to April 2021, Mr. Abrams served as the Chief Financial Officer for RiseIT Solutions, Inc. where he helped return the biness to profitability. From August 2009 to February 2019, Mr. Abrams served as the Chief Financial Officer of FitLife Brands, Inc., a publicly traded entity focused on the development of functional nutritional supplements to support an active, healthy lifestyle. Mr. Abrams earned his M.B.A. with Honors from the Booth School of Biness at the University of Chicago and received his B.B.A. with Honors from the University of Massachetts at Amherst as a William F. Field Alumni Scholar.- Michael Abrams，于2021年5月至2025年1月期间，在上市的生物技术公司Arch Therapeutics，Inc.担任首席财务官的TERM1，在短暂过渡角色后，他于2025年2月3日辞去该公司的职务。从2019年2月到2021年4月，Abrams先生在RiseIT Solutions，Inc.担任首席财务官，帮助该业务恢复盈利。从2009年8月至2019年2月，Abrams先生担任FitLife Brands，Inc.的首席财务官，该公司是一家上市实体，专注于开发功能性营养补充剂，以支持积极、健康的生活方式。艾布拉姆斯先生在芝加哥大学布斯商学院以优异成绩获得工商管理硕士学位，并以William F. Field校友学者的身份在马萨诸塞大学阿默斯特分校以优异成绩获得工商管理硕士学位。
- Michael Abrams has served as Chief Financial Officer since November 2024. Prior to his appointment as Chief Financial Officer, Mr. Abrams served as the Chief Financial Officer of Arch Therapeutics, Inc., a publicly traded biotechnology company, from May 2021 through January 2025, which he resigned from on February 3, 2025 after a brief transitional role. From February 2019 to April 2021, Mr. Abrams served as the Chief Financial Officer for RiseIT Solutions, Inc. where he helped return the biness to profitability. From August 2009 to February 2019, Mr. Abrams served as the Chief Financial Officer of FitLife Brands, Inc., a publicly traded entity focused on the development of functional nutritional supplements to support an active, healthy lifestyle. Mr. Abrams earned his M.B.A. with Honors from the Booth School of Biness at the University of Chicago and received his B.B.A. with Honors from the University of Massachetts at Amherst as a William F. Field Alumni Scholar.
- Joseph Casper
Joseph M. Casper，曾担任多个高级领导职务。Casper先生曾在德勤和第一咨询集团担任咨询领导职务，为大型组织和学术医疗中心提供咨询服务。他的专业经验还包括与主要付款人和提供者组织合作，包括Kaiser Permanente和Anthem。他还与俄亥俄州克利夫兰大学医学中心等学术医疗中心广泛合作。Casper先生是早期病历聚合平台的共同发明者，该平台最终扩展到为超过1500万患者提供服务。2016年至2021年期间，他曾在医疗保健人工智能公司Ingine Inc.的董事会任职。自2019年以来，他一直在专注于老年生活技术的公司ThriveWell Tech的董事会任职。此外，自2021年以来，他一直担任图罗大学的董事会成员，通过其整骨医学和健康与人类服务学院支持医师和护理教育。此外，自2022年以来，他一直担任SureTest，Inc.的董事会成员，该公司为健康系统和企业软件环境开发和提供智能测试自动化解决方案。2023年3月至2025年8月期间，Casper先生担任Ryte AI的首席战略官，该公司是由人工智能驱动的医疗保健数据分析平台。此前，Casper先生曾担任白血病学会西北分会主席，任期两年。他的经历涵盖了从早期公司到价值数十亿美元的企业等多个组织。
Joseph Casper has served as Chief Operational Officer since January 2026. Prior to joining the Company, Mr. Casper has held vario senior leadership positions. Mr. Casper has served in consulting leadership positions with Deloitte and First Consulting Group, where he advised large organizations and academic medical centers. His professional experience also includes work with major payer and provider organizations, including Kaiser Permanente and Anthem. He also worked extensively with academic medical centers such as the University Medical Center, Cleveland, Ohio. Mr. Casper is the co inventor of an early medical record aggregation platform that ultimately scaled to serve more than 15 million patients. Beten 2016 to 2021, he served on the board of directors of Ingine Inc., a healthcare artificial intelligence company. Since 2019, he has been serving on the board of directors of Thrivell Tech, a company focused on senior living technologies. Further, since 2021, he has been serving on the board of directors of To University, supporting physician and nursing education through its Colleges of Osteopathic Medicine and Health and Human Services. Additionally, since 2022, he has been serving on the board of directors of SureTest, Inc., a company that develops and delivers intelligent test automation solutions for health systems and enterprise software environments. Beten March 2023 and August 2025, Mr. Casper served as the Chief Strategy Officer of Ryte AI, artificial intelligence pored healthcare data analytics platform. Previoly, Mr. Casper served a two year term as Chairman of the Leukemia Society, Northst Chapter. His experience spans organizations ranging from early stage companies to multi billion dollar enterprises.- Joseph M. Casper，曾担任多个高级领导职务。Casper先生曾在德勤和第一咨询集团担任咨询领导职务，为大型组织和学术医疗中心提供咨询服务。他的专业经验还包括与主要付款人和提供者组织合作，包括Kaiser Permanente和Anthem。他还与俄亥俄州克利夫兰大学医学中心等学术医疗中心广泛合作。Casper先生是早期病历聚合平台的共同发明者，该平台最终扩展到为超过1500万患者提供服务。2016年至2021年期间，他曾在医疗保健人工智能公司Ingine Inc.的董事会任职。自2019年以来，他一直在专注于老年生活技术的公司ThriveWell Tech的董事会任职。此外，自2021年以来，他一直担任图罗大学的董事会成员，通过其整骨医学和健康与人类服务学院支持医师和护理教育。此外，自2022年以来，他一直担任SureTest，Inc.的董事会成员，该公司为健康系统和企业软件环境开发和提供智能测试自动化解决方案。2023年3月至2025年8月期间，Casper先生担任Ryte AI的首席战略官，该公司是由人工智能驱动的医疗保健数据分析平台。此前，Casper先生曾担任白血病学会西北分会主席，任期两年。他的经历涵盖了从早期公司到价值数十亿美元的企业等多个组织。
- Joseph Casper has served as Chief Operational Officer since January 2026. Prior to joining the Company, Mr. Casper has held vario senior leadership positions. Mr. Casper has served in consulting leadership positions with Deloitte and First Consulting Group, where he advised large organizations and academic medical centers. His professional experience also includes work with major payer and provider organizations, including Kaiser Permanente and Anthem. He also worked extensively with academic medical centers such as the University Medical Center, Cleveland, Ohio. Mr. Casper is the co inventor of an early medical record aggregation platform that ultimately scaled to serve more than 15 million patients. Beten 2016 to 2021, he served on the board of directors of Ingine Inc., a healthcare artificial intelligence company. Since 2019, he has been serving on the board of directors of Thrivell Tech, a company focused on senior living technologies. Further, since 2021, he has been serving on the board of directors of To University, supporting physician and nursing education through its Colleges of Osteopathic Medicine and Health and Human Services. Additionally, since 2022, he has been serving on the board of directors of SureTest, Inc., a company that develops and delivers intelligent test automation solutions for health systems and enterprise software environments. Beten March 2023 and August 2025, Mr. Casper served as the Chief Strategy Officer of Ryte AI, artificial intelligence pored healthcare data analytics platform. Previoly, Mr. Casper served a two year term as Chairman of the Leukemia Society, Northst Chapter. His experience spans organizations ranging from early stage companies to multi billion dollar enterprises.